Category - Developments

Developments

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Clearside Biomedical (NASDAQ:CLSD) reported positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX, an axitinib injectable suspension, which is administered by suprachoroidal...

June 15, 2021

Developments

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Lucid Psycheceuticals inked a world-wide license agreement with Toronto’s University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications...

June 14, 2021

Developments

Hepion Pharmaceuticals to be added to the Russell Microcap Index

Hepion Pharmaceuticals (NASDAQ:HEPA) is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28. Membership in the...

June 9, 2021

Developments

Veterinary healthcare company evaluating IntelGenx VetaFilm platform

IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a materials transfer agreement with an undisclosed global veterinary healthcare company to evaluate IntelGenx’s proprietary VetaFilm platform in cats. Based on a successful...

June 8, 2021

Developments

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

The FDA registered the laboratory of Dipanjan Pan, Ph.D., at the University of Maryland School of Medicine, as an approved laboratory development site for RNA Disease Diagnostics’ (RNADD) Antisense COVID-19 molecular...

June 3, 2021

Developments

Lancet article discusses benefits of PharmaJet Tropis ID needle-free delivery

A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV) and...

June 3, 2021

Developments

Lineage reports additional cases of retinal tissue restoration in dry AMD with OpRegen

Lineage Cell Therapeutics (NASDAQ, TASE:LCTX) reported that restoration of retinal tissue was observed in two additional patients enrolled in the company’s Phase 1/2a study of its lead product candidate, OpRegen. ...

June 1, 2021

Developments

Ripple Therapeutics polymer-free drug delivery published in Nature Communications

An article describing Ripple Therapeutics’ Epidel technology platform entitled, “Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery,” was recently published in the peer-reviewed...

June 1, 2021

Developments

Seelos receives European orphan drug designation for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency Committee for Orphan Medicinal Products. Under orphan...

May 27, 2021

Developments

KA Imaging in U.S. distribution pact with Alpha Imaging

KA Imaging signed a U.S. distribution agreement with Ohio-based Alpha Imaging for its Reveal 35C portable dual-energy X-ray detector. Alpha Imaging is one of the largest distributors of medical imaging equipment in the...

May 26, 2021

Category - Developments

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Hepion Pharmaceuticals to be added to the Russell Microcap Index

Veterinary healthcare company evaluating IntelGenx VetaFilm platform

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

Lancet article discusses benefits of PharmaJet Tropis ID needle-free delivery

Lineage reports additional cases of retinal tissue restoration in dry AMD with OpRegen

Ripple Therapeutics polymer-free drug delivery published in Nature Communications

Seelos receives European orphan drug designation for SLS-005 in ALS

KA Imaging in U.S. distribution pact with Alpha Imaging

General

More